Krystal Biotech (KRYS) Net Cash Flow (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Net Cash Flow of -$71.7 million for Q2 2026, down 263.05% year-over-year from $44.0 million in Q2 2025, and down 1231.58% on a QoQ basis from $6.3 million in Q1 2026.
Krystal Biotech (KRYS) Net Cash Flow (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Net Cash Flow for 11 years, with the latest figure at -$71.7 million in Q2 2026.
- Net Cash Flow for Q2 2026 came in at -$71.7 million, down 263.05% year-over-year; the trailing twelve-month figure through Jun 2026 was $78.0 million (up 995.59% YoY), and the FY2025 annual result was $151.2 million, up 1262.27% from the prior year.
- Net Cash Flow eased to -$71.7 million in Q2 2026, from $6.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $135.1 million in Q2 2023 and troughed at -$71.9 million in Q1 2022.
- A 5-year average of $5.0 million and a median of -$13.8 million in 2023 frame the typical range for Net Cash Flow.
- The largest YoY upside for Net Cash Flow was 466.0% in 2025 against a maximum downside of 7486.15% in 2025.
- A 5-year view of Net Cash Flow shows it stood at -$24.5 million in 2022, then surged by 39.62% to -$14.8 million in 2023, then plunged by 92.97% to -$28.5 million in 2024, then soared by 466.0% to $104.3 million in 2025, then plunged by 168.76% to -$71.7 million in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were -$71.7 million in Q2 2026, $6.3 million in Q1 2026, and $104.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | -71.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -71.74 Mn |
| Jun 30, 2026 | -71.74 Mn |
| Mar 31, 2026 | 6.34 Mn |
| Mar 31, 2026 | 6.34 Mn |
| Dec 31, 2025 | 104.34 Mn |
| Dec 31, 2025 | 104.34 Mn |
| Sep 30, 2025 | 39.08 Mn |
| Sep 30, 2025 | 39.08 Mn |
| Jun 30, 2025 | 44.00 Mn |
| Jun 30, 2025 | 44.00 Mn |
| Mar 31, 2025 | -36.27 Mn |
| Mar 31, 2025 | -36.27 Mn |
| Dec 31, 2024 | -28.51 Mn |
| Dec 31, 2024 | -28.51 Mn |
| Sep 30, 2024 | 27.89 Mn |
| Sep 30, 2024 | 27.89 Mn |
| Jun 30, 2024 | -12.88 Mn |
| Jun 30, 2024 | -12.88 Mn |
| Mar 31, 2024 | 491,000.00 |
| Mar 31, 2024 | 491,000.00 |